tiprankstipranks

BofA says Phase 3 MDD trial miss has ‘no impact’ on Axsome price target

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a monotherapy, BofA says the firm continues to ascribe zero value to the Sunosi-MDD opportunity which it continues to see as “high risk” following the Phase 3 update. The firm, which reiterates a Buy rating and $174 price target on the shares, believes Axsome’s product pipeline “remains underappreciated at current trading levels,” the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue